Feuerstein-Ratain RuleA few points about the Feuerstein-Ratain Rule.
Whatever truth there is to the Feuerstein-Ratain Rule, that truth is already built into the Bioasis share price. If (when?) we prove that we are an exception to that "rule" then you can likely shift the decimal place in our share price over to the right, probably a couple of notches.
If we did eventually move today's share price over a couple of notches, say, to even $10.00, then we would be in the "large pharma" catagory that Feuerstein and Ratain rave about.
And here's a telling
quote from Feuerstein of Feuerstein-Ratain Rule fame. He posted:
"
First, a reminder about the Feuerstein-Ratain (F-R) Rule: University of Chicago oncologist and professor Dr. Mark Ratain and I examined 59 phase III clinical trials of cancer drugs going back 10 years. We found companies with micro-cap market valuations (i.e. market caps less than $300 million) had no chance -- 0% -- of producing positive phase III results."
That 0% chance statement is logically wrong. It's the drug, itself, that succeeds or fails in clinical trials, not the company. The determinant is the drug.
Secondly, that statement is a false conclusion. Their study revealed that 59 clinical trials failed. It's a logical fallacy to conclude from that historical assessment that small companies have "no chance -- 0% -- of producing positive phase III results." The odds don't look good but it's wrong to say the odds are zero. One success will blow that nonsense out of the air.
Finally, if the Feuerstein-Ratain Rule had any real truth to it, then the FDA, venture capitalists and the investing public would all work to prevent all small companies from ever taking their drugs past phase 1 or 2. It's clear that has not happened, and, therefore, the Feuerstein-Ratain Rule is not being given much credence in either the marketplace or the clinic.
Let's think, just because we can and should, that Bioasis is the company that puts the Feuerstein-Ratain Rule to bed, once and for all.